Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2017.07.008
Abstract: BACKGROUND AIMS Activated NK cells (aNK) generated by expansion of a human interleukin-2-dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity. This phase 1 study evaluated feasibility, safety, and activity of aNK… read more here.
Keywords: ank cells; cell; refractory relapsed; patients refractory ... See more keywords